Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pandemic travel issues or Covid quarantine. It happens. Unfortunate but the exciting news still exists and can be disseminated promptly this week.
Cancer drugs likely to see no impact:
Mike Bailey, director of research at FBB Capital Partners and a former health-care analyst at Stifel, said it appears the FDA has fared better than expected through the pandemic even though the risk of a backlog remains.
He said he doubts there will be substantial delays for new cancer drugs and medicines for rare diseases as those continue to be a high priority for the agency.
He said that may not be true for lower priority pharmaceutical areas such as generics, and he’s heard some concerns from those in the medical device industry about deadlines slipping.
Premarket on a Monday most likely. Too much to allow for dissemination by longs and shorts to announce on a Friday. Harms the impact that a Monday would allow.
After attending last year's meeting, that was exactly how it was run with discussions, q&a, executives discussing their area of expertise. However this year, given the sensitive nature of the trial conclusion being so close, Geert could not risk a slip up with ANY kind of revelation about what they may or may not know. Gavin already was misinterpreted with the 297 number, or maybe not. So the muzzles have to stay on till they can get clearance to be more open again.
Ergomed upgraded from ADD to BUY at Numis. New price target 500p versus 395p close today, a 26% premium expectation.
This report this morning sounds like IDMC already stated to continue till number of events is reached.
https://www.prnewswire.com/news-releases/biotechs-strive-to-combat-rising-cancer-mortality-rates-300932759.html
FYI since they reported it:
https://www.marketscreener.com/ERGOMED-PLC-16917574/news/Ergomed-Board-Change-29221194/
Yes, all of these big institutions that are running billions in ETF products have to allocate their allotted percentage to CVM. Vanguard will be the same way when they report. All of their Russell ETF's that had exposure to the index CVM joined were big buyers last quarter and are just reporting now. Doesn't mean there aren't some small/midcap portfolio managers also buying under their own freedom to do so in their open end funds. Just that their purchases are dwarfed by the ETF ones.
Be careful on the BlackRock news. They are the sponsor and creator of I-shares, many of which are tied to the exact type of indexes and allocation percentages as the Russell inclusions. They had to buy CVM for those. Was not just for open-ended mutual fund portfolio manager accumulation based on news or speculation.
FYI on Zimmerman at BIO Philly yesterday (friend attended). All about LEAPS, and well received. Nothing on Multikine. 15 min presentation. Slides on technology and study hopefully leading to NDA submission. No handouts. Full room about 25 attendees.
FYI (from an upcoming attendee) - BIO 2019 Philadelphia - Wed. June 5th - 5:00-5:15pm - Theater 3 - Dr. Dan Zimmerman - Cel-Sci Corp.
Interpreting some of today's discussion by being at the meeting, I'm confident the company is completely blinded to the trial results, feel confident in the longer the 298 has not happened, and expect a positive outcome. They want to prove to everyone that they believed, they did the study right, took no shortcuts, and are confident that this can and should be an eventual standard of care. They did bring up the 10% complete response for eliminating tumors in Phase 2 and are excited to see if it was replicated in Phase 3. Geert did happen to say that the outcome is an "asymmetrical risk" that shareholders are investing in a company that could produce a "50x price jump or lose a lot of money". He also mentioned he gets lots of offers for funding. Several a week and that he's talking to "interesting people". He's not expecting any major offer before data readout. Although he did say if Buffett showed up tomorrow and wanted a $50MM piece, he might take the meeting. They are hopeful that the FDA will deem the product non-toxic also (the only ones that can indicate that), because they feel confident it is. Geert explained how unlikely there could be any competition that would be able to catch up and replicate their formula and trial history to be in the mix. And lastly, he indicated he was at some convention/seminar up in Canada the last few days and all they wanted to talk about was Cel-Sci.
Used to be Micro, now Small, on the way to Mid? :)
What is a mid-cap stock?
Mid caps are typically defined as companies with market caps that are between $2 billion and $10 billion. Mid-cap stocks tend to be riskier than large-cap stocks but less risky than small-cap stocks. Mid-cap stocks, however, tend to offer more growth potential than large-cap stocks.
What are small-cap stocks?
Small caps are typically defined as companies with market caps that are less than $2 billion. Many small caps are young companies with significant growth potential. However, the risk of failure is greater with small-cap stocks than with large-cap and mid-cap stocks. As a result, small-cap stocks tend to be the more volatile (and therefore riskier) than large-cap and mid-cap stocks. Historically, small-cap stocks have typically underperformed large-cap stocks during recessions but have outperformed large-cap stocks as the economy has emerged from recessions.
The smallest stocks of the small caps are called micro-cap and nano-cap stocks.
Micro-cap stocks ($50 million to $2 billion in market capitalization) and nano-cap stocks (market caps less than $50 million) are even riskier than small-cap stocks. While the opportunity for these companies to experience extreme growth is great, the risk to lose a large amount of money is also possible.